Campaigners demand right to generic version of breast cancer drugBMJ 2015; 351 doi: https://doi.org/10.1136/bmj.h5279 (Published 05 October 2015) Cite this as: BMJ 2015;351:h5279
- Zosia Kmietowicz
- 1The BMJ
A group campaigning for better access to new and expensive cancer drugs has called on the health secretary, Jeremy Hunt, to scrap the patent for a breast cancer drug and allow a generic version to be made available.1
Kadcyla (also known as T-DM1 and marketed by Roche) is a combination of trastuzumab (Herceptin) and the cytotoxic agent DM1 for women with HER2 positive metastatic breast cancer.
From 4 November no new patients in the United Kingdom will be able to access Kadcyla because it was de-listed from the Cancer Drugs Fund in September to help stem spiralling costs in the scheme.2 The drug …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial